EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 103 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,620,704 | -56.7% | 8,592,471 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $6,049,099 | -16.0% | 8,592,471 | +7.0% | 0.00% | 0.0% |
| Q1 2023 | $7,199,893 | +12.0% | 8,027,532 | +47.4% | 0.00% | 0.0% |
| Q4 2022 | $6,426,000 | -89.4% | 5,444,756 | -32.6% | 0.00% | -90.9% |
| Q3 2022 | $60,801,000 | +25.7% | 8,074,297 | +5.2% | 0.02% | +29.4% |
| Q2 2022 | $48,356,000 | -22.3% | 7,675,577 | +2.4% | 0.02% | -5.6% |
| Q1 2022 | $62,208,000 | +70.1% | 7,495,063 | +6.4% | 0.02% | +80.0% |
| Q4 2021 | $36,563,000 | -7.4% | 7,044,734 | +19.2% | 0.01% | -23.1% |
| Q3 2021 | $39,476,000 | -16.0% | 5,909,661 | +7.2% | 0.01% | -13.3% |
| Q2 2021 | $46,987,000 | +19.3% | 5,515,031 | +23.9% | 0.02% | +15.4% |
| Q1 2021 | $39,376,000 | -18.3% | 4,450,241 | +13.5% | 0.01% | -23.5% |
| Q4 2020 | $48,198,000 | +325.4% | 3,921,835 | +181.7% | 0.02% | +240.0% |
| Q3 2020 | $11,331,000 | – | 1,392,055 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Telemetry Investments, L.L.C. | 135,848 | $2,024,000 | 6.74% |
| INTERWEST VENTURE MANAGEMENT CO | 764,918 | $11,397,000 | 4.91% |
| Knoll Capital Management, LLC | 350,238 | $5,219,000 | 3.85% |
| 683 Capital Management, LLC | 1,850,000 | $27,565,000 | 3.15% |
| Soleus Capital Management, L.P. | 205,407 | $3,060,000 | 2.95% |
| Broadfin Capital, LLC | 1,236,368 | $18,422,000 | 2.47% |
| P.A.W. CAPITAL CORP | 144,000 | $2,146,000 | 2.29% |
| MANGROVE PARTNERS IM, LLC | 847,284 | $12,625,000 | 1.85% |
| Corriente Advisors, LLC | 203,898 | $3,038,000 | 1.63% |
| Trellus Management Company, LLC | 63,850 | $951,000 | 1.59% |